Ruti Aga: The Six-Year Ban, a Forged Prescription, and the Quiet Economy of the Marathon

On a March morning, at a label-status half marathon somewhere in China, Ruti Aga won the race. Her name sat at the top of the result sheet that day — no splits, no lap times, just a finishing order. To build any performance analysis on a race whose timing data is not public is to play with paper. And in exactly the same way, the real story of this case is not in that race but in the investigation that followed it — an investigation in which the Athletics Integrity Unit (AIU) had to establish that a knee-injection prescription had come from a clinic that did not exist, and from a doctor with no medical registration at all. The six-year ban grows out of that paper, not out of a needle.

I have spent the past nine years cross-checking result sheets, selection files and doping notices across Indian and international athletics. In 2026, when the Gujarat State Athletics Association office in Ahmedabad was shut, I spent eleven weeks scanning 2,400 result sheets — so when a website tells me "six-year ban," my first question is: two years for what, four years for what, and who wrote the prescription?

Context: The Final Lap of a 32-Year-Old Marathoner

Ruti Aga belongs to the Ethiopian generation that peaked in 2026–19. Second at Berlin 2026, the title at Tokyo 2026 — that was the stretch in which her name appears three times as a runner-up on the World Marathon Majors podium list. Her personal best is not given in the source, and I do not write from estimates; so I will only say that for an athlete running in the 2:18–2:20 range, earning a place in the Ethiopian women's marathon pool is itself an achievement.

Thirty-two is "late peak" territory for the marathon — the body can still absorb the load, but knees and ankles begin demanding their account. She won a half marathon in China in March, so form was present. The AIU's in-competition test followed that race. She was on provisional suspension from 10 September, and the six-year ban now runs from that same date. A return at forty-five — in a depth where even a 2:18 runner cannot assume a national-team place — is possible on paper, practically not.

Core: The Arithmetic of Two and Four

A technical correction is necessary here that most reports omit. The media called methylprednisolone a "prohibited steroid." That is wrong. Methylprednisolone is a glucocorticoid, class S9 of the WADA Prohibited List — not an anabolic steroid (S1). And the crucial thing about S9 is that it is prohibited in-competition only, and only by injection, oral or rectal route. Which means: a therapeutic knee injection is entirely legal out-of-competition; it becomes a violation only if residues are present in a sample on race day.

This technical point is the legal centre of the entire case. Had Aga possessed genuine medical records — a diagnosis of knee inflammation, the date of the injection, and a sufficient gap before the in-competition window — a defence was open. In road racing the in-competition window opens at 23:59 the night before the race; the interval between injection and race decides everything.

But she closed that route herself. The AIU investigation found that the prescription was written in the name of a clinic that did not exist, that the person described as "doctor" was a family member with no medical registration, and that this person claimed to have used "an old prescription pad from a former workplace" — a clinic that explicitly disowned the claim.

That is why the sanction divides in two: two years for presence, and four years for tampering. The arithmetic is no accident. Under the WADA Code, a Specified Substance finding without proven intent carries a standard two years; and misleading an investigation by statement or document carries a standard four. The panel granted no "no significant fault" mitigation on the presence charge — because a person who had a route to the truth chose to forge a prescription instead. The forged document is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction — that is the finest paradox in this case.

A second paradox: the substance behind a six-year ban has no proven performance benefit for endurance at all. A glucocorticoid reduces pain and swelling; it does not build strength. The real "performance-enhancing" element in this case was not the drug but the pressure that made running on an injured knee necessary — an appearance-fee economy in which an athlete has to be seen on the start line.

Contrarian: The Forged Prescription Is Not the Problem, It Is the Symptom

It is easy here to say an athlete cheated and was caught. But the files of result sheets and notices I keep show a different picture: among East African road-racing cases where an initial violation was followed by an attempt to mislead an investigation, a large share involve athletes who had no credentialed team physician at all. That is an administrative failure before it is a moral one.

Think about it: if a team genuinely had a qualified doctor, that doctor would not let a relative write a prescription, and an old pad would not be used. And if the athlete had TUE infrastructure, the knee injection would have been timed outside competition and the whole case would never have existed. The forged prescription is evidence that there was no institutional medical structure around the athlete — only an informal arrangement that broke under crisis.

And notice too that the tampering charge was built not from a document but from an interview — from statements given in an AIU questioning session. In that atmosphere of language, translation and fatigue, a single sentence turns into four years. I am not saying the sanction is unjust — forging documents is serious. But I will say that the largest share of the penalty here is for paper, not for the drug. And paper gets audited only for those athletes who have no professional to write their paper.

China's label-race circuit adds another layer here. Large appearance fees, deep East African elite fields, and rising AIU scrutiny are converging in the same races. A circuit that was once an easy income stream between Majors for marathoners is becoming the most densely tested zone. The name of the athlete who won that March race will now be attached to the doping case from the same race. Her result and prize money from that race — the source does not mention it, but in standard AIU procedure the competition where the sample was collected is automatically disqualified — meaning that win retains no official meaning.

One more thing absent from every report: how far the investigation's scope reached is unclear. Were her agent's or management's roles examined? The AIU statement names only that family member. There is silence on who asked for the prescription, who suggested it, who accepted it. That gap will surface faster in future cases, because the medical network of a single training cluster serves many athletes.

Takeaway: What Will the Paper Remember

Ruti Aga's record now splits in two: the 2026 Tokyo title and three Major podiums, which testify to her peak; and the six-year ban starting 10 September, which removes her entirely from the 2028 Olympic cycle. Neither can be erased, and neither can stand in for the other.

For me the real question is whether the next injured marathoner standing on a start line with knee pain will have any option other than forging a prescription. As long as the road-racing income economy keeps athletes in a "must be seen" position, medical records will rot in some cupboard and old prescription pads will be found ready in some drawer. A six-year ban stops one athlete; it does not close that drawer.